Company intelligence
4BIO Capital
London-based venture fund investing in advanced therapies
About 4BIO Capital
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com
Verified activity
Signals from 4BIO Capital
3 published signals
Capital & Finance
4BIO Capital led an upsized and oversubscribed $33 million seed financing of Cloverleaf Bio to advance its novel class of engineered tRNA-based therapeutics for cancer.
Reported by 4BIO Capital
People
4BIO Capital supported Austin Draycott and the rest of the Cloverleaf team as they advance toward the clinic.
Reported by Dima Kuzmin
Capital & Finance
4BIO Capital led Cloverleaf Bio's $33M seed round.
Reported by Dima Kuzmin